[
  {
    "ts": null,
    "headline": "AMG TimesSquare Small Cap Growth Fund Q1 2025 Commentary",
    "summary": "AMG TimesSquare Small Cap Growth Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=96514e00bbf051b224fa8528a502367da060b1d9afc56228846548140e450fd0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751065500,
      "headline": "AMG TimesSquare Small Cap Growth Fund Q1 2025 Commentary",
      "id": 135600760,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=96514e00bbf051b224fa8528a502367da060b1d9afc56228846548140e450fd0"
    }
  },
  {
    "ts": null,
    "headline": "AMG TimesSquare Mid Cap Growth Fund Q1 2025 Commentary",
    "summary": "The AMG TimesSquare Mid Cap Growth Fund (Class I) returned -3.48% for Q1 of 2025 vs. -7.12% for the benchmark. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=f9cd25006737e4521033f7ec42929d8ae756d3f1e1c4af24a0a8f9894b752ba6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751063400,
      "headline": "AMG TimesSquare Mid Cap Growth Fund Q1 2025 Commentary",
      "id": 135600511,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194476600/image_2194476600.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The AMG TimesSquare Mid Cap Growth Fund (Class I) returned -3.48% for Q1 of 2025 vs. -7.12% for the benchmark. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=f9cd25006737e4521033f7ec42929d8ae756d3f1e1c4af24a0a8f9894b752ba6"
    }
  },
  {
    "ts": null,
    "headline": "US FDA eliminates risk evaluation and mitigation strategies for CAR-T cancer therapies",
    "summary": "The U.S. Food and DrugAdministration said on Friday it had eliminated the riskevaluation and mitigation strategies , a safety program toprotect patients from risky drugs, for currently approved...",
    "url": "https://finnhub.io/api/news?id=9ef6254ce18bfdd94bbb08202b537ac9debf639887ba16f0f2acb607818b1fb8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751043568,
      "headline": "US FDA eliminates risk evaluation and mitigation strategies for CAR-T cancer therapies",
      "id": 135597557,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "The U.S. Food and DrugAdministration said on Friday it had eliminated the riskevaluation and mitigation strategies , a safety program toprotect patients from risky drugs, for currently approved...",
      "url": "https://finnhub.io/api/news?id=9ef6254ce18bfdd94bbb08202b537ac9debf639887ba16f0f2acb607818b1fb8"
    }
  },
  {
    "ts": null,
    "headline": "Here's What to Expect From Johnson & Johnson's Next Earnings Report",
    "summary": "Johnson & Johnson is set to unveil its Q2 results in the upcoming month, and analysts expect its profitability to observe a notable decline.",
    "url": "https://finnhub.io/api/news?id=199675790b353d7a828bd751acaad05c5784b9807dab08d6ee60d855865e5c79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751017081,
      "headline": "Here's What to Expect From Johnson & Johnson's Next Earnings Report",
      "id": 135599279,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson is set to unveil its Q2 results in the upcoming month, and analysts expect its profitability to observe a notable decline.",
      "url": "https://finnhub.io/api/news?id=199675790b353d7a828bd751acaad05c5784b9807dab08d6ee60d855865e5c79"
    }
  },
  {
    "ts": null,
    "headline": "Victory Munder Mid-Cap Core Growth Fund Q1 2025 Commentary",
    "summary": "Victory Munder Mid-Cap Core Growth Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=83ef200e6d14f730c1ba9e437aee33b59afe7e1f3c03b49eb5d5796412834a7c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751015760,
      "headline": "Victory Munder Mid-Cap Core Growth Fund Q1 2025 Commentary",
      "id": 135590315,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=83ef200e6d14f730c1ba9e437aee33b59afe7e1f3c03b49eb5d5796412834a7c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.",
    "summary": "Johnson & Johnson (NYSE: JNJ) is an iconic U.S. healthcare giant.  There are a lot of positives with J&J, as it is more commonly known on Wall Street, but there's one dark cloud that I can't ignore.  J&J's streak is a huge 63 years, making it a Dividend King.",
    "url": "https://finnhub.io/api/news?id=9d379e0df1dd4837b7dabf5b9e156a51d62e06954f8a51b5a51bb59e2272b22a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751011920,
      "headline": "Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.",
      "id": 135585752,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) is an iconic U.S. healthcare giant.  There are a lot of positives with J&J, as it is more commonly known on Wall Street, but there's one dark cloud that I can't ignore.  J&J's streak is a huge 63 years, making it a Dividend King.",
      "url": "https://finnhub.io/api/news?id=9d379e0df1dd4837b7dabf5b9e156a51d62e06954f8a51b5a51bb59e2272b22a"
    }
  },
  {
    "ts": null,
    "headline": "How PepsiCo, Johnson & Johnson, And Skyworks Solutions Can Put Cash In Your Pocket",
    "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. PepsiCo, Johnson & Johnson, and Skyworks Solutions have rewarded shareholders for years and recently announced dividend ...",
    "url": "https://finnhub.io/api/news?id=c603f06dff5b6be629d8ce2981e01461f7f52e8e053c54a1e3356091ac3473f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751001372,
      "headline": "How PepsiCo, Johnson & Johnson, And Skyworks Solutions Can Put Cash In Your Pocket",
      "id": 135581824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. PepsiCo, Johnson & Johnson, and Skyworks Solutions have rewarded shareholders for years and recently announced dividend ...",
      "url": "https://finnhub.io/api/news?id=c603f06dff5b6be629d8ce2981e01461f7f52e8e053c54a1e3356091ac3473f4"
    }
  },
  {
    "ts": null,
    "headline": "Why JNJ Is a Long-Term Winner",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the Best Wide Moat Dividend Stocks to Invest in. Johnson & Johnson (NYSE:JNJ) is a long-established leader in the healthcare industry, with a strong portfolio of high-performing drugs in areas like immunology and cancer treatment, along with a thriving medical devices business. In 2023, the company separated its […]",
    "url": "https://finnhub.io/api/news?id=33fe06771f0ffc7ebf9aa641991116a5509242b649d4230b7eb0847aa92b24b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750986208,
      "headline": "Why JNJ Is a Long-Term Winner",
      "id": 135581825,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the Best Wide Moat Dividend Stocks to Invest in. Johnson & Johnson (NYSE:JNJ) is a long-established leader in the healthcare industry, with a strong portfolio of high-performing drugs in areas like immunology and cancer treatment, along with a thriving medical devices business. In 2023, the company separated its […]",
      "url": "https://finnhub.io/api/news?id=33fe06771f0ffc7ebf9aa641991116a5509242b649d4230b7eb0847aa92b24b8"
    }
  }
]